Orexo AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Orexo announces launch of Abstral in Japan
Orexo AB:Says Kyowa Hakko Kirin Co., Ltd (KHK) has commenced the launch of Abstral in Japan.Says Abstral will be jointly distributed by KHK and Hisamitsu Pharmaceutical Co.Says Orexo will receive a single digit royalty on net sales of Abstral in Japan.Says the manufacturing and marketing approval of Abstral in Japan was received on Sept. 20, 2013.
Latest Developments for Orexo AB
- Orexo AB completed its private placement
- Orexo AB streamlines operations in Uppsala
- Orexo presents data from a Phase 3 clinical trial that demonstrates that Zubsolv is as effective as Suboxone film in the treatment of opioid dependence
- Orexo AB announces positive top-line results from two phase 3 clinical trials that Assessed Zubsolv for induction of Buprenorphine Maintenance Therapy
- Share this
- Digg this